New pill aims to recolor white patches in vitiligo patients

NCT ID NCT07172347

Recruiting now Disease control Sponsor: Jiangsu vcare pharmaceutical technology co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called VC005 in 120 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants will take either VC005 or a placebo daily for 52 weeks. The main goal is to see if the drug can reduce the size of white patches on the face after 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VC005 tablets
What this could lead to: If it works, this could lead to a new treatment option that helps restore skin color in people with vitiligo.
What could go wrong: This is an early Phase 2 trial with only 120 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SEGMENTAL VITILIGO are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SEGMENTAL VITILIGO

Contacts and locations

Locations

The Peking University People's Hospital
RECRUITING

Beijing, Beijng, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.